Medical & Pharma Meetings>Continuing Medical Education

FDA Issues Final REMS

The long-awaited final version of the FDA’s opioid risk evaluation and mitigation strategy includes an educational “blueprint,” new opportunities for continuing medical education providers.

Sue Pelletier | Jul 12, 2012

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments

Load More

Comments

Plain text